Shield Therapeutics (GB:STX) has released an update.
Shield Therapeutics, a specialty pharmaceutical company focused on treating iron deficiency, has reported a substantial increase in Accrufer prescriptions, with total revenue in 2023 reaching $17.5m, nearly tripling from the previous year. The company has strengthened its financial position through a new $10m accounts receivable financing and improved terms associated with existing debt financing. Looking ahead, Shield Therapeutics anticipates becoming cashflow positive in the second half of 2025, signaling promising growth prospects for investors.
For further insights into GB:STX stock, check out TipRanks’ Stock Analysis page.
